Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer

Ferrari, N., Mohammed, Z. M. A., Nixon, C., Mason, S. M., Mallon, E., McMillan, D. C. , Morris, J. S. , Cameron, E. R. , Edwards, J. and Blyth, K. (2014) Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS ONE, 9(6), e100759. (doi:10.1371/journal.pone.0100759) (PMID:24967588) (PMCID:PMC4072705)

[img]
Preview
Text
95843.pdf - Published Version
Available under License Creative Commons Attribution.

4MB

Publisher's URL: http://dx.doi.org/10.1371/journal.pone.0100759

Abstract

The RUNX1 transcription factor is widely recognised for its tumour suppressor effects in leukaemia. Recently a putative link to breast cancer has started to emerge, however the function of RUNX1 in breast cancer is still unknown. To investigate if RUNX1 expression was important to clinical outcome in primary breast tumours a tissue microarray (TMA) containing biopsies from 483 patients with primary operable invasive ductal breast cancer was stained by immunohistochemistry. RUNX1 was associated with progesterone receptor (PR)-positive tumours (P<0.05), more tumour CD4+(P<0.05) and CD8+(P<0.01) T-lymphocytic infiltrate, increased tumour CD138+plasma cell (P<0.01) and more CD68+macrophage infiltrate (P<0.001). RUNX1 expression did not influence outcome of oestrogen receptor (ER)-positive or HER2-positive disease, however on univariate analysis a high RUNX1 protein was significantly associated with poorer cancer-specific survival in patients with ER-negative (P<0.05) and with triple negative (TN) invasive breast cancer (P<0.05). Furthermore, multivariate Cox regression analysis of cancer-specific survival showed a trend towards significance in ER-negative patients (P<0.1) and was significant in triple negative patients (P<0.05). Of relevance, triple negative breast cancer currently lacks good biomarkers and patients with this subtype do not benefit from the option of targeted therapy unlike patients with ER-positive or HER2-positive disease. Using multivariate analysis RUNX1 was identified as an independent prognostic marker in the triple negative subgroup. Overall, our study identifies RUNX1 as a new prognostic indicator correlating with poor prognosis specifically in the triple negative subtype of human breast cancer.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Nixon, Mr Colin and Mallon, Dr Elizabeth and Blyth, Professor Karen and Cameron, Professor Ewan and Mohammed, Dr Zahra and Edwards, Professor Joanne and Ferrari, Mr Nicola and Morris, Professor Joanna and McMillan, Professor Donald and Mason, Ms Susan
Authors: Ferrari, N., Mohammed, Z. M. A., Nixon, C., Mason, S. M., Mallon, E., McMillan, D. C., Morris, J. S., Cameron, E. R., Edwards, J., and Blyth, K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
College of Medical Veterinary and Life Sciences > School of Veterinary Medicine
Journal Name:PLoS ONE
Publisher:Public Library of Science
ISSN:1932-6203
Copyright Holders:Copyright © 2014 The Authors
First Published:First published in PLoS One 9(6):e100759
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record